Sangamo’s disruptive lead compounds have been on the back burner for a while now. Can new partnerships provide the lift they need?
Recent earnings report highlights key factors for future profitability.
Oral multiple sclerosis therapy Tecfidera makes all the difference as Biogen Idec's revenue and profit climb by 39% and 56%, respectively, in the fourth quarter.
Biogen, Amgen, and Omeros could all loom large in health care headlines this morning. Here's why.
Sector Update: Healthcare Shares Flat Pre-Market; Teva Pharmaceuticals up 4% on FDA Approval for Copaxone
Pre-Market Earnings Report for January 29, 2014 : BA, BIIB, DOW, EMC, PSX, PX, SO, VLO, HES, MPC, WLP, NVS
Oral MS treatments from Sanofi (SNY), Novartis (NVS), and Biogen (BIIB) will jockey for position overseas this year.See More Articles...